Russia has announced that its experimental cancer vaccine, Enteromix, has completed preclinical trials and demonstrated “high efficacy,” according to reports from state media. Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), stated at the Eastern Economic Forum in Vladivostok that the vaccine is “ready for use” and awaits official approval. Preclinical results, she claimed, confirmed safety and significant effectiveness, though no human trials have been disclosed.
The vaccine targets colorectal cancer, with additional research underway for glioblastoma and melanoma. However, scientific experts caution that claims of 100% efficacy lack verification. Dr. David James Pinato, a clinician scientist at Imperial College London, emphasized that preclinical testing in animals does not guarantee human success, noting discrepancies between animal immune systems and human cancer complexity.
Russian officials have not provided detailed data on the vaccine’s development timeline or clinical trial phases. Independent confirmation of its safety and efficacy remains pending.